Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients

This open-label, longitudinal, long-term study of de novo pediatric renal transplant recipients was designed to investigate the pharmacokinetics (PK) of mycophenolic acid (MPA) and its possible interaction with cyclosporine (CsA). Thirty-four children on an immunosuppressive regimen of CsA, prednisone, and mycophenolate mofetil (MMF, 300-400 mg/m ² twice daily) were investigated at 6, 30, 180, and 360 days after transplantation. Considerable interindividual variability in the areas under the concentration curve (AUC _(0-12)) of MPA was observed during the follow-up, although the dose of MMF remained the same over the same time. Predose levels (C0) increased significantly during the first 6 months after transplantation: C0 at 6 and 180 days after transplantation was 0.8 ± 0.6 and 1.9 ± 1.1 μg/mL (P <.0001). A significant time-dependent increase in the AUC of MPA was also observed during the first 6 posttransplant months: AUC _(0-12) at 6 and 180 days after transplantation was 23.3 ± 10.8 and 40 ± 11.6 mg*h/L (P = .003). MPA concentrations 3 and 4 hours after MMF intake were the individual time points that best correlated with the full MPA AUC (r = 0.8 and 0.79; P <.001). The abbreviated MPA AUC (0-4 hours) correlated reasonably with the full AUC (r = 0.87; P <.001). Finally, a significant reduction in CsA dose during the first 6 posttransplant months (P <.001) matched the significant increases in both MPA C0 and full MPA AUC, thus demonstrating the interaction of the 2 immunosuppressive drugs. These observations suggest the need for therapeutic drug monitoring when adjusting the dose of MMF in children.